cardiology
DAPT Decision Tool (Ticagrelor vs Clopidogrel)
Choice of P2Y12 inhibitor with aspirin after acute coronary syndrome, per the ESC 2023 ACS guideline.
References
- Byrne RA et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826.
- Wallentin L et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes (PLATO). N Engl J Med. 2009;361(11):1045–1057.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Clopidogrel (Loading Dose) · P2Y12 Inhibitor Antiplatelet — ACS
- Clopidogrel (Elderly) · Antiplatelet — P2Y12 Inhibitor
- Clopidogrel (Stroke/TIA Secondary Prevention) · Antiplatelet (P2Y12 Inhibitor)
- Clopidogrel · Antiplatelet (P2Y12 ADP receptor antagonist)
- Ticagrelor · Antiplatelet (reversible P2Y12 inhibitor)
- Ticagrelor · Antiplatelet
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.